Rasagiline

Evidence Level: L5

Predicted Indications: 6

Rasagiline

Pharmacist Assessment Report

Rasagiline: From Parkinson Disease to PLA2G6-Associated Neurodegeneration

One-Sentence Summary

Rasagiline is an irreversible MAO-B inhibitor, originally used to treat Parkinson disease and related parkinsonian syndromes. The TxGNN model predicts it may be effective for PLA2G6-associated neurodegeneration, but no clinical trials and no publications currently support this direction. The prediction rests on model output alone.

Quick Overview

Item	Content
Original Indication	Parkinson disease (the data compiled for this report also lists related parkinsonian syndromes; no approved indication text is available from Indian licences)
Predicted New Indication	PLA2G6-associated neurodegeneration
TxGNN Prediction Score	0.9971
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (9 of 9) – CDSCO approval status is not included in this data
Number of Listed Products	9 (valid: 9)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, rasagiline is an irreversible MAO-B inhibitor. It raises dopamine availability in the brain and provides symptomatic relief in Parkinson disease.

PLA2G6-associated neurodegeneration includes infantile neuroaxonal dystrophy and PLA2G6-related dystonia-parkinsonism (PARK14). A plausible link therefore exists for the parkinsonian features of the late-onset forms.

However, the underlying pathology (defective phospholipid remodelling, iron accumulation, alpha-synuclein pathology) is not addressed by MAO-B inhibition. The very high score likely reflects network proximity to the parkinsonism indications rather than disease-modifying biology. At best, the drug might offer symptomatic benefit in selected patients.

Other predictions reviewed (all without trials or literature):

Predicted Indication	TxGNN Score	Evidence Level	Assessment
Paralysis agitans, juvenile, of Hunt	0.9925	L5	Within the parkinsonism spectrum. This is closer to an extension of the existing indication than true repurposing, and needs juvenile and paediatric safety and efficacy confirmation. Recommendation: Research Question
Rasmussen subacute encephalitis	0.9956	L5	No clear mechanistic rationale for a T-cell-mediated disease. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence
Myelitis	0.9932	L5	No established anti-inflammatory role. Only indirect preclinical neuroprotection
Transaldolase deficiency	0.9919	L5	No mechanistic link. Hepatic involvement would need caution given rasagiline’s CYP1A2 metabolism
Perisylvian polymicrogyria with cerebellar hypoplasia and arthrogryposis	0.9901	L5	A structural malformation is not expected to respond to a symptomatic MAO-B inhibitor

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
6734	Afrelect 0.5mg Tablet (Taj Pharma India Ltd)	Strip of 10 tablets	Not specified
184809	Relgin 1 Tablet (Intas Pharmaceuticals Ltd)	Strip of 10 tablets	Not specified
184402	Rasalect 1 Tablet (Sun Pharmaceutical Industries Ltd)	Strip of 10 tablets	Not specified
184676	Relgin 0.5 Tablet (Intas Pharmaceuticals Ltd)	Strip of 10 tablets	Not specified
189515	Rasagin 0.5mg Tablet (Natco Pharma Ltd)	Strip of 30 tablets	Not specified

Nine valid single-ingredient oral registrations exist in total; the five above are shown.

Safety Considerations

Contraindications (from the knowledge graph, not label text): hypertension and hypertensive disorder; multiple system atrophy; postural orthostatic tachycardia syndrome; orthostatic hypotension; drug-induced dyskinesia; epilepsy; bipolar disorder and major affective disorder; liver disease; gallbladder disease; melanoma; phaeochromocytoma and sympathetic paraganglioma; and several cancers (duodenum, small intestine, heart, adrenal gland).
Drug Interactions: 137 interactions were recorded. Examples:
- Major: bupropion, morphine.
- Moderate: epinephrine, cimetidine, phentermine, diethylpropion, dronabinol, obeticholic acid, chlorpropamide, glimepiride, and multiple insulin products (aspart, degludec, detemir, glargine, glulisine, human isophane, human regular, inhaled).

Please refer to the package insert for full label warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a model score, with no clinical trials or literature. The mechanistic link is weak because MAO-B inhibition does not address the core pathology of PLA2G6-associated neurodegeneration. The juvenile parkinsonism prediction is the most coherent but is essentially an extension of the existing indication.

To proceed, the following is needed:

Package insert warnings and contraindications for the Indian products (a blocking gap for safety screening)
Detailed mechanism of action data
Case series, natural-history data, or preclinical evidence for MAO-B inhibition in PLA2G6-related dystonia-parkinsonism
Juvenile and paediatric safety and efficacy data if the juvenile parkinsonism direction is pursued
Review of hepatic safety, since liver disease appears among the graph-derived contraindications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.